中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

36 records (took 0.039 seconds)

    Heparin and sulfatide binding peptides from the type-I repeats of human thrombospondin and conjugates thereof
    11.
    发明授权
    Heparin and sulfatide binding peptides from the type-I repeats of human thrombospondin and conjugates thereof 失效
    来自人类血小板反应蛋白I型重复序列的肝素和硫苷脂结合肽及其结合物

    公开(公告)号：US06051549A

    公开(公告)日：2000-04-18

    申请号：US41119

    申请日：1998-03-11

    Applicant: David D. Roberts ,  Henry C. Krutzsch ,  Nenghua Guo

    Inventor： David D. Roberts ,  Henry C. Krutzsch ,  Nenghua Guo

    IPC: A61K38/00 ,  C07K7/00 ,  C07K14/78 ,  C07K17/10

    CPC classification number: C07K17/10 ,  C07K14/78 ,  A61K38/00 ,  C12N2533/50 ,  Y10S514/908

    Abstract: This invention identifies a biologically active group of peptide sequences from Type I repeat units of the extracellular matrix protein, human thrombospondin-1, identical or homologous to the sequence, KRFKQDGGWSHWSPWSSC (SEQ ID NO.30). The biological activities residing with the full sequences, portions thereof, and variants of the full or partial sequences are disclosed. The invention describes how biological activity may be enhanced by covalently linking these peptides to suitable carriers, preferably a branched, water-soluble polymer of low (or absent) toxicity and immunogenicity, such as polysucrose (Ficoll.TM.). The invention describes (1) a method for preparing such conjugates, (2) the use of the defined peptides or their conjugates in blocking or modifying the action on cellular processes of heparin (e.g., proliferation, adhesion, motility, extravasation and neovascularization), sulfatides, related sulfated glycoconjugates, fibronectin, and basic fibroblast growth factor, involving malignant cell lines and normal endothelial cells. Use of the defined peptides, analogs or peptidomimetics and their conjugates for treatment of metastatic tumors, breast carcinomas, melanomas, Kaposi's sarcomas, hemangiomas, diabetic retinopathies, and various pathological conditions dependent upon neovascularization is also disclosed.

    Abstract translation: 本发明鉴定了与序列KRFKQDGGWSHWSPWSSC（SEQ ID NO.30）相同或同源的细胞外基质蛋白I型重复单元的人类血小板反应蛋白-1的生物活性肽肽序列。 公开了其完整序列，部分和全部或部分序列的变体的生物活性。 本发明描述如何通过将这些肽共价连接到合适的载体，优选具有低（或不存在）毒性和免疫原性的支链水溶性聚合物如聚蔗糖（Ficoll TM）来增强生物活性。 本发明描述了（1）制备这种缀合物的方法，（2）使用所定义的肽或其缀合物来阻断或改变对肝素细胞过程的作用（例如增殖，粘附，运动，外渗和新生血管形成） 硫酸盐，相关的硫酸化糖缀合物，纤连蛋白和碱性成纤维细胞生长因子，涉及恶性细胞系和正常内皮细胞。 还公开了定义的肽，类似物或肽模拟物及其缀合物用于治疗转移性肿瘤，乳腺癌，黑素瘤，卡波西氏肉瘤，血管瘤，糖尿病视网膜病变以及依赖于新生血管形成的各种病理状况的用途。

    Planar recording head having formed yokes
    12.
    发明授权
    Planar recording head having formed yokes 失效
    具有形成磁轭的平面记录头

    公开(公告)号：US6008969A

    公开(公告)日：1999-12-28

    申请号：US993719

    申请日：1997-12-18

    Applicant: Darren T. Imai ,  David D. Roberts ,  Dimitre A. Latev ,  William C. Cain

    Inventor： Darren T. Imai ,  David D. Roberts ,  Dimitre A. Latev ,  William C. Cain

    IPC: G11B5/31 ,  G11B5/60

    CPC classification number: G11B5/3183 ,  G11B5/3163

    Abstract: A planar thin film magnetic head comprises an insulating substrate, a pair of insulating pedestals formed on the substrate, a top magnetic yoke having a central portion disposed over the substrate and having opposite ends supported on each of the pedestals. A conductor is provided over the top yoke central portion, and an insulating layer is disposed between the conductor and the top magnetic yoke. A bottom magnetic yoke is disposed over the conductor and has a gap in a central portion and opposite ends in contact with the top yoke ends.

    Abstract translation: 平面薄膜磁头包括绝缘基板，形成在基板上的一对绝缘基座，顶部磁轭，其中心部分设置在基板上并具有支撑在每个基座上的相对端部。 导体设置在顶部磁轭中心部分之上，绝缘层设置在导体和顶部磁轭之间。 底部磁轭设置在导体上方，并且在中心部分具有间隙，并且相对端部与顶部磁轭端部接触。

    Prevention of tissue ischemia, related methods and compositions
    15.
    发明授权
    Prevention of tissue ischemia, related methods and compositions 有权
    预防组织缺血，相关方法和组合物

    公开(公告)号：US08236313B2

    公开(公告)日：2012-08-07

    申请号：US12444364

    申请日：2007-10-05

    Applicant: Jeffrey S. Isenberg ,  David D. Roberts ,  William A. Frazier

    Inventor： Jeffrey S. Isenberg ,  David D. Roberts ,  William A. Frazier

    IPC: A61K39/395

    CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  B01J21/063 ,  B01J21/12 ,  B01J23/002 ,  B01J23/30 ,  B01J27/188 ,  B01J37/0205 ,  B01J2523/00 ,  C07C45/002 ,  C07C45/52 ,  C07C51/235 ,  C07C51/252 ,  C07C253/26 ,  C07K14/78 ,  C07K2317/76 ,  G01N33/6887 ,  G01N33/6893 ,  G01N2333/705 ,  C07C47/22 ,  C07C57/04 ,  B01J2523/15 ,  B01J2523/51 ,  B01J2523/69 ,  B01J2523/41

    Abstract: Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death. The therapeutics identified herein allow for precise regulation of blood flow to tissues and organs which need it, while substantially avoiding systemic complications. Methods and compositions described herein can be used to increase tissue survival under conditions of trauma and surgery, as well as conditions of chronic vascular disease. Also disclosed are methods for the treatment of elderly subjects using agents that affect TSP1 and CD47 and thereby affect tissue perfusion. Additionally, provided herein are compositions and methods for influencing blood coagulation, allowing for controlled increased or decreased blood clotting. Additionally, provided herein are compositions and methods for decreasing blood flow, as in the case of cancer through mimicking the effects of TSP1 and CD47 on blood vessel diameter and blood flow.

    Abstract translation: 本文提供的是用于预防，改善和/或减少由于缺血引起的组织缺血和/或组织损伤，增加血管直径，血流量和组织灌注的组合物和方法，所述血管疾病包括外周血管疾病，动脉粥样硬化性血管疾病 ，冠状动脉疾病，中风和影响其他病症，通过抑制CD47和/或阻断TSP1和/或CD47活性或相互作用。 影响CD47-TSP1在血管中的相互作用允许控制血管直径和血流量，并允许改变血压和心脏功能。 在血液流量减少的情况下，例如通过损伤或动脉粥样硬化，阻断TSP1-CD47相互作用使血管扩张并增加血流量，组织灌注和组织存活。 这又减少或预防组织坏死和死亡。 本文鉴定的治疗剂允许精确调节需要它的组织和器官的血流，同时基本上避免系统并发症。 本文描述的方法和组合物可用于在创伤和手术的条件下以及慢性血管疾病的病症中增加组织存活。 还公开了使用影响TSP1和CD47并因此影响组织灌注的试剂治疗老年受试者的方法。 此外，本文提供了影响血液凝固的组合物和方法，允许控制增加或减少血液凝固。 此外，本文提供的是通过模拟TSP1和CD47对血管直径和血流量的影响来减少血流量的组合物和方法，如在癌症的情况下。

    Method and tool for handling micro-mechanical structures
    16.
    发明授权
    Method and tool for handling micro-mechanical structures 失效
    用于处理微机械结构的方法和工具

    公开(公告)号：US5966591A

    公开(公告)日：1999-10-12

    申请号：US908648

    申请日：1997-08-07

    Applicant: David D. Roberts

    Inventor： David D. Roberts

    IPC: H01L21/00 ,  H01L21/673 ,  H01L21/44

    CPC classification number: H01L21/67138 ,  B81C99/002

    Abstract: A method of forming and handling an array of micro-devices such as thin film devices that enables simultaneous mass handling and processing of these thin film devices. A plurality of micro-devices and links are simultaneously formed on a wafer, with the links interconnecting the micro-devices for maintaining a unitary array structure. A matrix of magnetic strips is then formed to impart added overall tensile strength to the array. The magnetic strips are secured to the links and form a planar support grid therewith. The array of micro-devices is then released from the wafer and lifted therefrom by means of a magnetic pick-up tool. Using the pick-up tool, the array is transferred onto a magnetic chuck which securely retains the array. Conductive wires are bonded to a row of micro-devices devices which are then separated from the array into individual micro-devices.

    Abstract translation: 一种形成和处理诸如薄膜器件的微器件阵列的方法，其能够同时进行质量处理和处理这些薄膜器件。 多个微器件和链节同时形成在晶片上，其中链节互连微器件以维持整体阵列结构。 然后形成磁条矩阵以赋予阵列增加的总拉伸强度。 磁条被固定到链节上并与其形成平面支撑格栅。 然后将微器件阵列从晶片释放并通过磁力拾取工具从其上提升。 使用拾取工具，将阵列转移到牢固地保持阵列的磁性卡盘上。 导电线结合到一排微器件器件，然后将其从阵列分离成单独的微器件。

    Carbohydrate receptor for bacteria and method for use thereof
    17.
    发明授权
    Carbohydrate receptor for bacteria and method for use thereof 失效
    细菌的碳水化合物受体及其使用方法

    公开(公告)号：US5386027A

    公开(公告)日：1995-01-31

    申请号：US60134

    申请日：1993-05-13

    Applicant: Howard C. Krivan ,  Victor Ginsburg ,  David D. Roberts

    Inventor： Howard C. Krivan ,  Victor Ginsburg ,  David D. Roberts

    IPC: A61K31/70 ,  G01N33/569 ,  C08B37/00 ,  A61K39/02

    CPC classification number: G01N33/56911 ,  A61K31/70 ,  Y10S435/803 ,  Y10S435/851 ,  Y10S435/874 ,  Y10S435/882 ,  Y10S435/885

    Abstract: A carbohydrate receptor for pathogenic bacteria is a purified carbohydrate compound that is a member selected from the group consisting of fucosyl-asialo GM1, asialo GM1, and asialo GM2. The receptor can be included in a composition having a pharmaceutically acceptable carrier. The receptor may be used for purifying, detecting, or removing bacteria from diseased tissue. The structure of the receptor is N-acetylagalctosamine-beta-1-4-galactose-beta-1-4-glucose, abbreviated GalNAc.beta.1-4Gal.beta.1-4Glc. The receptor is present in human and animal tissues as complex molecule and can serve as the attachment site for bacterial infection. For example, fucosyl-asialo GM1, asialo GM1, and asialo GM2 are three biological molecules which occur in cell membranes and contain the carbohydrate receptor.

    Abstract translation: 用于致病细菌的碳水化合物受体是选自岩藻糖基 - 脱ial GM1，脱ial GM1和唾液酸GM2的成员的纯化碳水化合物化合物。 受体可以包含在具有药学上可接受的载体的组合物中。 该受体可用于纯化，检测或从患病组织中除去细菌。 受体的结构是N-乙酰加己酰胺-β-1-4-半乳糖-β-1-4-葡萄糖，缩写为GalNAcβ1-4Galβ1-4Glc。 受体作为复合分子存在于人和动物组织中，可作为细菌感染的附着位点。 例如，岩藻糖基唾液酸GM1，脱ial GM1和脱ial GM2是发生在细胞膜中并含有碳水化合物受体的三种生物分子。

Patent Agency Ranking